Patents Assigned to Genzyme Corporation
  • Patent number: 9920318
    Abstract: The invention relates to isolation of novel ?-actin and ribosomal protein S21 (rpS21) promoters and uses thereof. In particular, this invention features nucleotide sequences for rodent ?-actin promoters including, hamster, rat, and mouse, and hamster rpS21 promoter.
    Type: Grant
    Filed: August 1, 2014
    Date of Patent: March 20, 2018
    Assignee: GENZYME CORPORATION
    Inventors: Scott D. Estes, Weiqun Zhang
  • Publication number: 20180065957
    Abstract: The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment of metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, cystic disease and for the treatment of cancer.
    Type: Application
    Filed: April 18, 2017
    Publication date: March 8, 2018
    Applicant: Genzyme Corporation
    Inventors: Elyse BOURQUE, Mario A. CABRERA-SALAZAR, Cassandra CELATKA, Seng H. CHENG, Bradford Hirth, Andrew GOOD, Katherine JANCSICS, John MARSHALL, Markus Metz, Ronald K. SCHEULE, Renato SKERLJ, Yibin XIANG, Zhong ZHAO, John LEONARD, Thomas NATOLI, Elina MAKINO, Herve HUSSON, Oxana BESKROVNAYA
  • Patent number: 9909101
    Abstract: Provided herein are methods of perfusion culturing an adherent mammalian cell using a shake flask and a plurality of microcarriers, and various methods that utilize these culturing methods.
    Type: Grant
    Filed: February 21, 2014
    Date of Patent: March 6, 2018
    Assignee: Genzyme Corporation
    Inventors: Jianguo Yang, Yang Yang, Jennifer Tengtrakool, Weichang Zhou
  • Publication number: 20180055916
    Abstract: The invention relates to dose escalation enzyme replacement therapy using acid sphingomyelinase (ASM) for the treatment of human subjects having acid sphingomyelinase deficiency (ASMD), and, in particular, patients with non-neurological manifestations of Niemann-Pick Disease (NPD), and in certain embodiments, NPD type B.
    Type: Application
    Filed: April 12, 2017
    Publication date: March 1, 2018
    Applicants: Icahn School of Medicine at Mount Sinai, Genzyme Corporation
    Inventors: Edward H. Schuchman, Robert J. Desnick, Gerald F. Cox, Laura P. Andrews, James M. Murray
  • Publication number: 20180055939
    Abstract: Stable pharmaceutical compositions comprising recombinant adeno-associated virus (AAV) virions are described. The compositions provide protection against loss of recombinant AAV vector genomes and transduceability under conditions such as exposure to cycles of freezing and thawing and storage in glass or polypropylene vials. The compositions comprise recombinant AAV virions in combination with one or more dihydric or polyhydric alcohols, and, optionally, a detergent, such as a sorbitan ester. Also described are methods of using the compositions.
    Type: Application
    Filed: March 28, 2017
    Publication date: March 1, 2018
    Applicant: Genzyme Corporation
    Inventors: Hema S. Sista, Yero J. Espinoza
  • Publication number: 20180051054
    Abstract: Provided herein are methods of processing a fluid that include the use of one or both of a circuit system including a tangential flow filtration (TFF) unit and a circuit system including a tangential flow virus filtration (TFVF) unit. Also provided are integrated and continuous processes for manufacturing a therapeutic protein drug substance that include a step of processing a fluid including the recombinant therapeutic protein using any of the methods provided herein.
    Type: Application
    Filed: August 15, 2017
    Publication date: February 22, 2018
    Applicant: Genzyme Corporation
    Inventors: Tarl Vetter, Michael Coolbaugh, Veena Warikoo, Konstantin Konstantinov
  • Patent number: 9895315
    Abstract: The tablets, compositions and methods of the present invention, comprising a carbonate salt of an aliphatic amine polymer and s monovalent anion can prevent or ameliorate acidosis, in particular acidosis in patients with renal disease. The tablets and compositions of the present invention maintain a disintegration time of no greater than 30 minutes at 37° C. and at pH of at least 1 for a period of at least ten weeks at 60° C. Furthermore, the tablets are stable for extended periods of time without the need for specialized storage conditions.
    Type: Grant
    Filed: December 14, 2016
    Date of Patent: February 20, 2018
    Assignee: Genzyme Corporation
    Inventors: Hitesh R. Bhagat, Jeffrey M. Goldberg, Abizer I. Harianawala, Louis Brenner
  • Publication number: 20180044412
    Abstract: A modified IgG antibody binds and neutralizes TGF?1 selectively and with high affinity and avidity. The modified IgG antibody comprises four polypeptide chains and may comprise modifications to the elbow regions of the polypeptide chains. The modified IgG antibody may comprise the same VH and VL domains or CDR regions as metelimumab. The modified IgG antibody is useful in therapeutic and diagnostic applications.
    Type: Application
    Filed: March 3, 2016
    Publication date: February 15, 2018
    Applicant: GENZYME CORPORATION
    Inventors: Huawei Qiu, Julie Bird
  • Patent number: 9890394
    Abstract: This disclosure provides methods and compositions for treating disorders or injuries that affect motor function and control in a subject. In one aspect, the invention a transgene product is delivered to a subject's spinal cord by administering a recombinant viral vector containing the transgene to the spinal cord. The viral vector delivers the transgene which expresses the encoded recombinant viral gene product. The viral gene product comprises HIF1-alpha. Also provided are compositions for delivery of a transgene product to a subject's spinal cord.
    Type: Grant
    Filed: April 3, 2009
    Date of Patent: February 13, 2018
    Assignee: GENZYME CORPORATION
    Inventors: Catherine O'Riordan, Samuel Wadsworth
  • Publication number: 20180000728
    Abstract: Pharmaceutical formulations with a tropomyosin-related kinase inhibitor (“Trk inhibitor”) are disclosed. The pharmaceutical formulations comprise 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-amine in microcrystalline suspension formulations in its monohydrate form, which shows improved characteristics over the anhydrate form, and in extended release formulations. The extended release pharmaceutical formulations comprise 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-amine-loaded microspheres.
    Type: Application
    Filed: December 17, 2015
    Publication date: January 4, 2018
    Applicant: GENZYME CORPORATION
    Inventors: Harvey LIEBERMAN, Donglai YANG, C. Michael PHILBROOK, Michael SANTOS, Chris HO
  • Publication number: 20170369541
    Abstract: The invention is related to methods of producing rod-derived cone viability factor (RdCVF). This invention also relates to the treatment of an ocular disease in a mammal using RdCVF. Also provided are expression vectors for high secreted expression of RdCVF of using nucleotide sequences encoding heterologous signal proteins and optionally markers for furin cleavage.
    Type: Application
    Filed: January 3, 2017
    Publication date: December 28, 2017
    Applicant: Genzyme Corporation
    Inventors: Catherine R. O'Riordan, William H. Brondyk
  • Publication number: 20170369583
    Abstract: The invention provides methods of treating lupus in a patient with an anti-CD52 antibody. Also includes are methods of increasing infiltration of regulatory T cells to affected sides of the patient's body, methods of reducing urine protein and/or albumin levels and methods of depleting lymphocytes to alleviate lupus symptoms.
    Type: Application
    Filed: March 1, 2017
    Publication date: December 28, 2017
    Applicant: GENZYME CORPORATION
    Inventors: Johanne M. Kaplan, Bruce L. Roberts, William M. Siders
  • Publication number: 20170349665
    Abstract: Anti-human CD52 antibodies and antigen-binding fragments thereof are provided. Also provided are isolated nucleic acids, recombinant vectors and host cells for making the antibodies and fragments. The antibodies and fragments can be used in therapeutic applications to treat, for example, autoimmune diseases, cancer, and graft rejection.
    Type: Application
    Filed: June 16, 2017
    Publication date: December 7, 2017
    Applicant: GENZYME CORPORATION
    Inventors: Huawei Qiu, Ronnie Rong Wei, Clark Qun Pan, Rebecca Sendak
  • Patent number: 9834604
    Abstract: The present invention provides a bispecific biologic comprising a ligand specific for CTLA-4 and a ligand specific for a pMHC complex.
    Type: Grant
    Filed: June 29, 2012
    Date of Patent: December 5, 2017
    Assignee: GENZYME CORPORATION
    Inventors: Yunxiang Zhu, Jozsef Karman, Ronnie Wei, Canwen Jiang, Seng Cheng
  • Publication number: 20170342144
    Abstract: Antibodies or antigen-binding fragments thereof are engineered to bind Transforming Growth Factor-? (TGF?). TGF?-isoform selective antibodies or antigen-binding fragments thereof may selectively bind human TGF?1, compared to human TGF?2 and human TGF?3, or may selectively bind human TGF?3, compared to human TGF?1 and human TGF?2. The design of the antibodies or antigen-binding fragments thereof is facilitated by a co-crystal structure of a recombinant Fab fragment of GC1008 bound to TGF?2 and by another co-crystal structure of the scFv version of GC1008 bound to TGF?1.
    Type: Application
    Filed: August 7, 2017
    Publication date: November 30, 2017
    Applicant: GENZYME CORPORATION
    Inventors: Ronnie Wei, Aaron Moulin, Magali Mathieu, Clark Pan, Sunghae Park, Huawei Qiu
  • Publication number: 20170334903
    Abstract: The invention relates to a method of preparing inhibitors of glucosylceramide synthase (GCS) useful for the treatment metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, and for the treatment of cancer.
    Type: Application
    Filed: May 12, 2017
    Publication date: November 23, 2017
    Applicant: Genzyme Corporation
    Inventors: Craig S. SIEGEL, Rayomand GIMI, Michael REARDON, Jin ZHAO
  • Publication number: 20170326172
    Abstract: A powder formulation comprises a pharmaceutically acceptable anionic stabilizer and an aliphatic amine polymer or a pharmaceutically acceptable salt thereof mixed with the anionic stabilizer. The powder formulation is conveniently packaged in a container, such as a sachet. A method of treating a subject with hyperphosphotemia with the powder formulation is also disclosed.
    Type: Application
    Filed: January 26, 2017
    Publication date: November 16, 2017
    Applicant: Genzyme Corporation
    Inventors: Hitesh R. Bhagat, Jeffrey M. Goldberg
  • Publication number: 20170326203
    Abstract: Novel methods for treating patients with autoimmune diseases are disclosed. The methods of the invention include first depleting circulating lymphocytes in the mammal, e.g., by administering anti-thymocyte antibody, and then, during the course of repopulation, administering to the mammal a therapeutically effective amount of latent TGF-? and/or another agent that promotes expansion of regulatory T cells. In certain aspects, the disclosed process results in improved kidney function and survival rates.
    Type: Application
    Filed: August 2, 2017
    Publication date: November 16, 2017
    Applicant: GENZYME CORPORATION
    Inventors: Johanne Kaplan, John M. McPherson
  • Patent number: 9815816
    Abstract: The present invention relates to chemical processes for the manufacture of certain quinazoline derivatives, or pharmaceutically acceptable salts thereof. The invention also relates to processes for the manufacture of certain intermediates useful in the manufacture of the quinazoline derivatives and to processes for the manufacture of the quinazoline derivatives utilizing said intermediates. In particular, the present invention relates to chemical processes and intermediates useful in the manufacture of the compound 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline.
    Type: Grant
    Filed: July 22, 2015
    Date of Patent: November 14, 2017
    Assignee: Genzyme Corporation
    Inventors: Jorgen Blixt, Michael David Golden, Philip John Hogan, David Michael Glanville Martin, Francis Joseph Montgomery, Zakariya Patel, John David Pittam, George Joseph Sependa, Christopher John Squire, Nicholas Cartwright Alexander Wright
  • Patent number: 9815892
    Abstract: Multimeric fusion proteins of an Ig-like domain of Flt-1 are rendered functional by inclusion of a linker moiety. Vectors encoding the fusion proteins and host cells expressing the fusion proteins can be used therapeutically to block neovascularization in individuals with pathological conditions related to neovascularization. Such conditions include age-related macular degeneration, cancer, psoriasis, proliferative diabetic retinopathy, asthma, uveitis, osteoarthritis, and rheumatoid arthritis. The same means of multimerization used for an Iglike domain of Flt-1, i.e., a linker and a multimerization domain, can be used for other polypeptides, including extracellular receptors, antibody variable regions, cytokines, chemokines, and growth factors.
    Type: Grant
    Filed: January 31, 2014
    Date of Patent: November 14, 2017
    Assignee: Genzyme Corporation
    Inventors: Abraham Scaria, Peter Pechan, Samuel Wadsworth